This document summarizes strategies for improving energy efficiency in applications that use hybrid programming models combining message passing and shared memory. It presents new execution schemes that consider dynamic concurrency throttling and dynamic voltage frequency scaling for hybrid models. Evaluation on NPB MZ benchmarks and ASC Sequoia applications achieved substantial average energy savings of 8.74% with some performance gains of up to 7.5% or negligible losses.
A novel statistical cost model and an algorithm for efficient application off...Finalyearprojects Toall
To get IEEE 2015-2017 Project for above title in .Net or Java
mail to finalyearprojects2all@gmail.com or contact +91 8870791415
IEEE 2015-2016 Project Videos: https://www.youtube.com/channel/UCyK6peTIU3wPIJxXD0MbNvA
A novel statistical cost model and an algorithm for efficient application off...Finalyearprojects Toall
To get IEEE 2015-2017 Project for above title in .Net or Java
mail to finalyearprojects2all@gmail.com or contact +91 8870791415
IEEE 2015-2016 Project Videos: https://www.youtube.com/channel/UCyK6peTIU3wPIJxXD0MbNvA
ABSTRACT
The main objective of present investigation is to formulate the sustained release tablet of Metoprolol Succinate
using 32 factorial design. Metoprolol Succinate, is a selective β1blocker, to treat Hypertension & Heart Failure. The
SR tablets of Metoprolol Succinate were prepared employing different concentrations of HPMCK15M and
HPMCK100M in different combinations as a rate retardants by Direct Compression technique using 32 factorial
design. The quantity of rate retarders, HPMCK15M and HPMCK100M required to achieve the desired drug release
was selected as independent variables, X1 and X2 respectively whereas, time required for 10% of drug dissolution
(t10%), 50% (t50%), 75% (t75%) and 90% (t90%) were selected as dependent variables. Totally nine formulations were
designed and are evaluated for hardness, friability, thickness, % drug content, In-vitro drug release. From the
Results it was concluded that all the formulation were found to be with in the Pharmacopoeial limits and the Invitro
dissolution profiles of all formulations were fitted in to different Kinetic models, the statistical parameters like
intercept (a), slope (b) & regression coefficient (r) were calculated. Polynomial equations were developed for t10%,
t50%, t75%, t90%. Validity of developed polynomial equations were verified by designing 2 check point formulations(C1,
C2). According to SUPAC guidelines the formulation (F5) containing combination of 10% HPMCK15M and 10%
HPMCK100M, is the most similar formulation (f2=92.38 & No significant difference, t= 0.0216) to marketed
product (Metocard). The selected formulation (F5) follows Higuchi’s kinetics, the mechanism of drug release was
found to be Super case II transport (Non-Fickian, n= 0.981).
Abstract: The main objective of present investigation is to formulate the sustained release
tablet of Rosiglitazone Maleate using 32 factorial design. Rosiglitazone Maleate, an oral antidiabetic
agent. The SR tablets of Rosiglitazone Maleate were prepared employing different
concentrations of HPMCK15M and Carboplol934P in different combinations as a rate
retardants by Direct Compression technique using 32 factorial design. The quantity/
concentration of Polymers , HPMCK15M and Carboplol934P required to achieve the desired
drug release was selected as independent variables, X1 and X2 respectively whereas, time
required for 10% of drug dissolution (t10%), 50% (t50%), 75% (t75%) and 90% (t90%) were
selected as dependent variables. Totally nine formulations were designed and are evaluated
for hardness, friability, thickness, % drug content, In-vitro drug release. From the Results it
was concluded that all the formulation were found to be with in the Pharmacopoeial limits
and the In-vitro dissolution profiles of all formulations were fitted in to different Kinetic
models, the statistical parameters like intercept (a), slope (b) & regression coefficient (r)
were calculated. Polynomial equations were developed for t10%, t50%, t75%, t90%. Validity of
developed polynomial equations were verified by designing 2 check point formulations(C1,
C2). According to SUPAC guidelines the formulation (F5) containing combination of 25%
HPMCK15M and 20% Carboplol934P, is the most similar formulation (similarity factor
f2=93.1376, dissimilarity factor f1= 1.7642 & No significant difference, t= 0.06949) to
marketed product (AVANDIA). The selected formulation (F5) follows Higuchi’s kinetics,
and the mechanism of drug release was found to be Fickian Diffusion (n= 0.417).
ABSTRACT
The main objective of present investigation is to formulate the sustained release tablet of Metoprolol Succinate
using 32 factorial design. Metoprolol Succinate, is a selective β1blocker, to treat Hypertension & Heart Failure. The
SR tablets of Metoprolol Succinate were prepared employing different concentrations of HPMCK15M and
HPMCK100M in different combinations as a rate retardants by Direct Compression technique using 32 factorial
design. The quantity of rate retarders, HPMCK15M and HPMCK100M required to achieve the desired drug release
was selected as independent variables, X1 and X2 respectively whereas, time required for 10% of drug dissolution
(t10%), 50% (t50%), 75% (t75%) and 90% (t90%) were selected as dependent variables. Totally nine formulations were
designed and are evaluated for hardness, friability, thickness, % drug content, In-vitro drug release. From the
Results it was concluded that all the formulation were found to be with in the Pharmacopoeial limits and the Invitro
dissolution profiles of all formulations were fitted in to different Kinetic models, the statistical parameters like
intercept (a), slope (b) & regression coefficient (r) were calculated. Polynomial equations were developed for t10%,
t50%, t75%, t90%. Validity of developed polynomial equations were verified by designing 2 check point formulations(C1,
C2). According to SUPAC guidelines the formulation (F5) containing combination of 10% HPMCK15M and 10%
HPMCK100M, is the most similar formulation (f2=92.38 & No significant difference, t= 0.0216) to marketed
product (Metocard). The selected formulation (F5) follows Higuchi’s kinetics, the mechanism of drug release was
found to be Super case II transport (Non-Fickian, n= 0.981).
Abstract: The main objective of present investigation is to formulate the sustained release
tablet of Rosiglitazone Maleate using 32 factorial design. Rosiglitazone Maleate, an oral antidiabetic
agent. The SR tablets of Rosiglitazone Maleate were prepared employing different
concentrations of HPMCK15M and Carboplol934P in different combinations as a rate
retardants by Direct Compression technique using 32 factorial design. The quantity/
concentration of Polymers , HPMCK15M and Carboplol934P required to achieve the desired
drug release was selected as independent variables, X1 and X2 respectively whereas, time
required for 10% of drug dissolution (t10%), 50% (t50%), 75% (t75%) and 90% (t90%) were
selected as dependent variables. Totally nine formulations were designed and are evaluated
for hardness, friability, thickness, % drug content, In-vitro drug release. From the Results it
was concluded that all the formulation were found to be with in the Pharmacopoeial limits
and the In-vitro dissolution profiles of all formulations were fitted in to different Kinetic
models, the statistical parameters like intercept (a), slope (b) & regression coefficient (r)
were calculated. Polynomial equations were developed for t10%, t50%, t75%, t90%. Validity of
developed polynomial equations were verified by designing 2 check point formulations(C1,
C2). According to SUPAC guidelines the formulation (F5) containing combination of 25%
HPMCK15M and 20% Carboplol934P, is the most similar formulation (similarity factor
f2=93.1376, dissimilarity factor f1= 1.7642 & No significant difference, t= 0.06949) to
marketed product (AVANDIA). The selected formulation (F5) follows Higuchi’s kinetics,
and the mechanism of drug release was found to be Fickian Diffusion (n= 0.417).
Bed side patients monitoring system with emergency alert
Strategies for energy efficient resource management of hybrid programming models
1. ECWAY TECHNOLOGIES
IEEE PROJECTS & SOFTWARE DEVELOPMENTS
OUR OFFICES @ CHENNAI / TRICHY / KARUR / ERODE / MADURAI / SALEM / COIMBATORE
CELL: +91 98949 17187, +91 875487 2111 / 3111 / 4111 / 5111 / 6111
VISIT: www.ecwayprojects.com MAIL TO: ecwaytechnologies@gmail.com
STRATEGIES FOR ENERGY-EFFICIENT RESOURCE MANAGEMENT OF
HYBRID PROGRAMMING MODELS
ABSTRACT:
Many scientific applications are programmed using hybrid programming models that use both
message passing and shared memory, due to the increasing prevalence of large-scale systems
with multicore, multisocket nodes. Previous work has shown that energy efficiency can be
improved using software-controlled execution schemes that consider both the programming
model and the power-aware execution capabilities of the system. However, such approaches
have focused on identifying optimal resource utilization for one programming model, either
shared memory or message passing, in isolation. The potential solution space, thus the challenge,
increases substantially when optimizing hybrid models since the possible resource configurations
increase exponentially. Nonetheless, with the accelerating adoption of hybrid programming
models, we increasingly need improved energy efficiency in hybrid parallel applications on
large-scale systems.
In this work, we present new software-controlled execution schemes that consider the effects of
dynamic concurrency throttling (DCT) and dynamic voltage and frequency scaling (DVFS) in
the context of hybrid programming models. Specifically, we present predictive models and novel
algorithms based on statistical analysis that anticipate application power and time requirements
under different concurrency and frequency configurations. We apply our models and methods to
the NPB MZ benchmarks and selected applications from the ASC Sequoia codes. Overall, we
achieve substantial energy savings (8.74 percent on average and up to 13.8 percent) with some
performance gain (up to 7.5 percent) or negligible performance loss.